Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-02-15
DOI
10.3389/fendo.2019.00080
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
- (2019) Darren K. McGuire et al. CIRCULATION
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY
- (2018) Alan J. Garber et al. Endocrine Practice
- The safety of gliptins : updated data in 2018
- (2018) André Jacques Scheen Expert Opinion On Drug Safety
- DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes
- (2018) Marco Bugliani et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
- (2018) Carolyn F. Deacon PEPTIDES
- Oxyntomodulin: Actions and role in diabetes
- (2018) Jens J. Holst et al. PEPTIDES
- Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
- (2018) Devram S. Ghorpade et al. NATURE
- Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition
- (2018) Elodie M. Varin et al. Cell Metabolism
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Insulin Secretion Depends on Intra-islet Glucagon Signaling
- (2018) Berit Svendsen et al. Cell Reports
- Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
- (2018) Chintan N. Koyani et al. Frontiers in Physiology
- Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line
- (2017) Veronica Sancho et al. PLoS One
- Pancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis
- (2017) Shuyang Traub et al. Cell Reports
- Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease
- (2017) Christian Baumeier et al. Molecular Metabolism
- Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors
- (2017) Yanqing Zhang et al. Scientific Reports
- Reduced DPP4 activity improves insulin signaling in primary human adipocytes
- (2016) Diana Röhrborn et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes
- (2016) Åsa Segerstolpe et al. Cell Metabolism
- HepaticDPP4DNA Methylation Associates With Fatty Liver
- (2016) Christian Baumeier et al. DIABETES
- Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist
- (2016) Michael A. Nauck et al. DIABETES
- Pancreatic Safety of Sitagliptin in the TECOS Study
- (2016) John B. Buse et al. DIABETES CARE
- Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
- (2016) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase-4 inhibitor development
- (2016) R. D. Carr DIABETIC MEDICINE
- Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
- (2016) Darren K. McGuire et al. JAMA Cardiology
- Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells
- (2015) Petra Augstein et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of high glucose on caveolin-1 and insulin signaling in 3T3-L1 adipocytes
- (2015) Sara Palacios-Ortega et al. Adipocyte
- Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets
- (2014) Liehua Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
- (2014) Michael Lehrke et al. CLINICAL THERAPEUTICS
- Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
- (2014) Itamar Raz et al. DIABETES CARE
- Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors
- (2014) K. Aaboe et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes
- (2014) Bilal A. Omar et al. DIABETOLOGIA
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- Quantification of Intact and Truncated Stromal Cell-Derived Factor-1α in Circulation by Immunoaffinity Enrichment and Tandem Mass Spectrometry
- (2014) Weixun Wang et al. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity
- (2013) Elisabetta Bianchi et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade
- (2013) B. A. Aulinger et al. DIABETES
- Adipose Dipeptidyl Peptidase-4 and Obesity: Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro
- (2013) H. Sell et al. DIABETES CARE
- The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses
- (2013) D. Anz et al. DIABETES OBESITY & METABOLISM
- Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
- (2013) Boaz Hirshberg et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- The DPP-4 Inhibitor Linagliptin Restores β-Cell Function and Survival in Human Isolated Islets Through GLP-1 Stabilization
- (2013) Payal Shah et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
- (2013) Samuel S. Engel et al. Diabetes Therapy
- A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets
- (2012) P. Marchetti et al. DIABETOLOGIA
- Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people
- (2012) Yasushi Kirino et al. ENDOCRINE JOURNAL
- Impaired Incretin-Induced Amplification of Insulin Secretion after Glucose Homeostatic Dysregulation in Healthy Subjects
- (2012) Katrine B. Hansen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
- (2011) D. Lamers et al. DIABETES
- The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients
- (2011) G. P. Fadini et al. DIABETES OBESITY & METABOLISM
- Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus—an adaptive response to hyperglycaemia?
- (2011) A. M. K. Hansen et al. DIABETOLOGIA
- Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival
- (2011) Z. Liu et al. DIABETOLOGIA
- Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?
- (2011) N M Whalley et al. JOURNAL OF ENDOCRINOLOGY
- Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism
- (2011) Masayuki Miyazaki Molecular Medicine Reports
- Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
- (2011) Helga Ellingsgaard et al. NATURE MEDICINE
- Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells
- (2010) Laura Pala et al. ACTA DIABETOLOGICA
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions
- (2010) L. Pala et al. DIABETIC MEDICINE
- The dipeptidyl peptidase IV family in cancer and cell biology
- (2010) Denise M. T. Yu et al. FEBS Journal
- Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents
- (2010) Y-L Liu et al. INTERNATIONAL JOURNAL OF OBESITY
- Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker
- (2010) Gábor Firneisz et al. PLoS One
- Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses
- (2009) Kalpit A Vora et al. BMC IMMUNOLOGY
- Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction
- (2009) Marc-Michael Zaruba et al. Cell Stem Cell
- Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
- (2009) K. Aaboe et al. DIABETES OBESITY & METABOLISM
- Stromal cell-derived factor-1 promotes survival of pancreatic beta cells by the stabilisation of beta-catenin and activation of transcription factor 7-like 2 (TCF7L2)
- (2009) Z. Liu et al. DIABETOLOGIA
- Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies
- (2009) Richard E. Pratley et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
- (2008) P. V. Højberg et al. DIABETOLOGIA
- Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
- (2008) Maralyn R. Druce et al. ENDOCRINOLOGY
- Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function
- (2008) Kei Ohnuma et al. TRENDS IN IMMUNOLOGY
- Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects
- (2007) Aine M. McKillop et al. DIABETES RESEARCH AND CLINICAL PRACTICE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now